Abstract
e15231 Background: Whereas BPC is potentially resectable, the risks of incomplete (R1) resection or early progression are high. Tumor response rate using GemOx in metastatic setting was of 27% with safety profile and CRT increase the rate of R0 resections. Aim: To evaluate feasibility and efficacy of a neoadjuvant therapy with GemOx+CRT in patients (pts) with BPC according to the MD Anderson classification. Methods: In this retrospective monocentric study, all eligible pts (PS<2, no contraindication for surgery) received 2 months of GemOx (gemcitabine 1000mg/m² D1, oxaliplatin 85 mg/m² D2, D1=D14); then, CRT (54 Gy+capecitabine) was administered in pts with tumor control. 2ndevaluation was done 1 month later to evaluate tumor resecability. Rate of treatment completion and resection, pathological response and disease free (DFS) and overall survival (OS) were analysed. Results: From 06/05 to 05/13, 72 pts (M= 38 [53%], median age 63 [42-80] yrs) received a median of 5[3-8] GemOx. After 1stevaluation, 17(24%...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
